title: Prognostic significance of accumulation of gene and chromosome alterations and histological grade in node-negative breast carcinoma.
abstract: The histological grade of atypia is a known prognostic indicator for breast cancer patients and correlates with many gene and chromosome alterations. To investigate the independent prognostic significance of gene and chromosome alterations in axillary node-negative (n0) breast cancers of the invasive ductal and invasive lobular types, the prevalence of eight gene and chromosome alterations and their association with histological grade and recurrence was studied in 129 consecutive patients who had undergone resection over an average follow-up period of 43.4 months. Loss of heterozygosity on 16q, 17p, 16p, 17q and 18q, p53 gene mutation and c-erbB-2 and int-2 gene amplifications were detected in 55%, 37%, 25%, 24%, 22%, 23%, 15% and 11% respectively. Individual alterations in 17p, 17q, 18q, c-erbB-2 and p53 were detected most frequently and gene and chromosome alterations tended to be accumulated in Grade 3 n0 invasive ductal/lobular carcinomas. Histological grade, 18q, int-2 and the number of these gene and chromosome alterations were significant prognostic indicators on Cox's univariate proportional hazard model, and 18q and int-2 were still significant after adjustment for histological grade. Results suggested that examination of the presence of certain gene and chromosome alterations, as well as histological grade, were effective in identifying n0 breast cancer patients at high risk of early recurrence.
authors.affiliation: Pathology Division, National Cancer Center Research Institute and Hospital, Tokyo, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Tsuda
authors.forename: C
authors.initials: C
authors.lastname: Sakamaki
authors.forename: S
authors.initials: S
authors.lastname: Tsugane
authors.forename: T
authors.initials: T
authors.lastname: Fukutomi
authors.forename: S
authors.initials: S
authors.lastname: Hirohashi
mesh_terms: D001943:Breast Neoplasms / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D002869:Chromosome Aberrations; D005260:Female; D051518:Fibroblast Growth Factor 3; D005346:Fibroblast Growth Factors / Q000235:genetics*; D018734:Genes, erbB-2; D016158:Genes, p53; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology*; D009154:Mutation; D009364:Neoplasm Recurrence, Local / Q000235:genetics; D009367:Neoplasm Staging; D011379:Prognosis; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D012306:Risk; D015996:Survival Rate
chemical_list: C496444:FGF3 protein, human; D051518:Fibroblast Growth Factor 3; D011518:Proto-Oncogene Proteins; D005346:Fibroblast Growth Factors